Single answer
Is Affimed NV (AFMD) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Affimed NV is $7.50, which is $7.32 (4,032.23%) above the current price today's price.
Low target: $5.00 | High target: $10.00
Company snapshot
A quick overview of the business and its public profile.
Affimed NV a clinicalstage biopharmaceutical company focuses on discovering and developing cancer immunotherapies in the United States Germany and rest of Europe Its lead product candidate is AFM13 which has completed Phase II clinical study for peripheral Tcell lymphoma in Phase IIa clinical trial for CD30positive lymphoma and in Phase I clinical trial for hodgkin lymphoma The company is also developing AFM24 a tetravalent bispecific epidermal growth factor receptor and CD16Abinding innate cell engager which is in Phase IIa clinical trial for the treatment of advanced cancers AFM28 an innate cell engager ICE which is in preclinical development to treat acute myeloid leukemia and AFM32 an ICE candidate that is in preclinical development for the treatment of solid tumors Affimed NV has collaboration agreements with The University of Texas MD Anderson Cancer Center Genentech Inc and Roivant Sciences Ltd as well as research funding agreement with The Leukemia Lymphoma Society The company was formerly known as Affimed Therapeutics BV and changed its name to Affimed NV in October 2014 Affimed NV was founded in 2000 and is headquartered in Heidelberg Germany
Website: https://www.affimed.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.20. Cash flow to debt ratio: -5.70. Net profit margin: -1,280.22%. Inflation risk score: high (0.85/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Affimed NV is $2.8M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Affimed NV, 2016-02-26 had a stock price of $32.80. If you invested back then, your return now would be a loss of $32.62 per share or 99.45%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.